nybanner

        Products

        API-Drug Peptide Linaclotide: A pill for bowel relief and comfort

        Short Description:

        Linaclotide is a breakthrough medication that can help you manage your chronic constipation and irritable bowel syndrome with constipation. It is made by Ironwood Pharmaceuticals, and has been approved by the FDA and other health authorities to be sold under the brand name Linzess in the US and Mexico, and as Constella in other countries. Linaclotide is a once-daily pill that you can take with or without food, and can help you have more frequent and complete bowel movements, and reduce the pain and discomfort caused by your condition.


        Product Detail

        Product Tags

        About This Item

        Linaclotide is a cyclic peptide that consists of 14 amino acids, three of which are cysteines that form disulfide bonds. Linaclotide is structurally related to the endogenous peptides guanylin and uroguanylin, which are natural ligands of the guanylate cyclase C (GC-C) receptor. The GC-C receptor is expressed on the luminal surface of the intestinal epithelial cells, where it regulates fluid secretion and intestinal motility. Linaclotide binds to the GC-C receptor with high affinity and specificity, and activates it by increasing the intracellular levels of cyclic guanosine monophosphate (cGMP). cGMP is a second messenger that mediates various cellular responses, such as chloride and bicarbonate secretion, smooth muscle relaxation, and pain modulation. Linaclotide acts locally in the gastrointestinal tract, and does not penetrate the blood-brain barrier or affect the central nervous system. Linaclotide also produces an active metabolite, MM-419447, which has similar pharmacological properties to linaclotide. Both linaclotide and its metabolite are resistant to proteolytic degradation by intestinal enzymes, and are mainly eliminated unchanged in the feces (MacDonald et al., Drugs, 2017).

        By activating the GC-C receptor, linaclotide increases the secretion of fluid into the intestinal lumen, which softens the stool and facilitates bowel movements. Linaclotide also reduces the visceral hypersensitivity and inflammation that are associated with irritable bowel syndrome (IBS) and other gastrointestinal disorders. Linaclotide modulates the activity of the enteric nervous system and the colonic nociceptors, which are sensory neurons that transmit pain signals from the gut to the brain. Linaclotide decreases the expression of pain-related genes, such as substance P and calcitonin gene-related peptide (CGRP), and increases the expression of opioid receptors, which mediate analgesia. Linaclotide also reduces the release of pro-inflammatory cytokines, such as interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α), and increases the release of anti-inflammatory cytokines, such as interleukin-10 (IL-10) and transforming growth factor beta (TGF-β). These effects of linaclotide improve the symptoms of constipation and abdominal pain in patients with IBS or chronic constipation (Lembo et al., The American Journal of Gastroenterology, 2018).

        Linaclotide has been shown to be effective and well-tolerated in several clinical trials involving patients with CC or IBS-C. In these trials, linaclotide improved bowel habits, such as stool frequency, consistency, and completeness; reduced abdominal pain and discomfort; and enhanced quality of life and patient satisfaction. Linaclotide also demonstrated a favorable safety profile, with diarrhea being the most common adverse event. The incidence of diarrhea was dose-dependent and usually mild to moderate in severity. Other adverse events were generally similar to placebo or low in frequency. No serious adverse events or deaths were attributed to linaclotide treatment (Rao et al., Clinical Gastroenterology and Hepatology, 2015).

        Product Dispaly

        shows (2)
        shows (3)
        shows (1)

        Why Choose Us

        Linaclotide is a novel and effective medication for patients with CC and IBS-C who have not responded well to conventional therapies. It works by mimicking the action of endogenous peptides that regulate intestinal function and sensation. Linaclotide can improve bowel habits, reduce abdominal pain, and enhance quality of life for these patients.

        productss

        Figure 1. Abdominal pain/abdominal discomfort and IBS degree of relief weekly responders over the 12-week. ?, placebo;?, linaclotide 290?μg.?
        (Yang, Y., Fang, J., Guo, X., Dai, N., Shen, X., Yang, Y., Sun, J., Bhandari, B. R., Reasner, D. S., Cronin, J. A., Currie, M. G., Johnston, J. M., Zeng, P., Montreewasuwat, N., Chen, G. Z., and Lim, S. (2018) Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions. Journal of Gastroenterology and Hepatology, 33: 980–989. doi: 10.1111/jgh.14086.)
        We are a polypeptide manufacturer in China, with several years of mature experience in polypeptide production. Hangzhou Taijia Biotech Co., Ltd. is a professional polypeptide raw material manufacturer, which can provide tens of thousands of polypeptide raw materials and can also be customized according to needs. The quality of polypeptide products is excellent, and the purity can reach 98%, which has been recognized by users all over the world.Welcome to consult us.


      1. Previous:
      2. Next:

      3. 主站蜘蛛池模板: 免费女人18毛片a级毛片视频| 国产精品日本一区二区不卡视频| 久久精品国产99国产精品| 男人激烈吮乳吃奶视频免费| 国产在线91精品入口| 91香蕉在线观看免费高清| 成人无码精品1区2区3区免费看| 亚洲youjizz| 激情综合色五月六月婷婷| 四虎影院2019| 91手机在线视频| 国产精品视频福利| yellow中文字幕在线高清| 日本乱子伦xxxx| 亚洲av永久无码精品三区在线4| 狠狠色综合久久婷婷| 四虎成人免费影院网址| 国产免费小视频| 国产经典三级在线| www亚洲视频| 无码专区久久综合久中文字幕| 亚洲av日韩综合一区久热| 波多野结衣女女互慰| 公交车上被弄进走不动| 色播影院性播免费看| 国产成人精品综合久久久久| 4hu四虎永久免在线视| 奇米小说首页图片区小说区| 中文字幕日韩在线观看| 日韩一区二区在线视频| 亚洲三级中文字幕| 欧美特黄a级高清免费大片| 伊人色综合久久88加勒| 精品欧洲男同同志videos| 国产亚洲一区二区在线观看| 国产真实乱xxxav| 国产精品无码电影在线观看| 99精品国产在热久久| 娇小枯瘦日本xxxx| 中文字幕亚洲综合久久菠萝蜜| 日本视频免费高清一本18|